EMA restricts use of MS medicine Zinbryta

[MSUK]

The European Medicines Agency (EMA) has provisionally restricted the use of multiple sclerosis (MS) drug Zinbryta (daclizumab) to patients with highly active relapsing remitting MS (RRMS) that has failed to respond to certain other treatment, and to patients with rapidly evolving relapsing MS who cannot be treated with other medicines...Read more - http://www.ms-uk.org/ema-restricts-use- ... yta-170717